Clinical Trial

Ondansetron Orodispersible Film for Vomiting Prevention in Pediatric Radiotherapy

Recruiting Phase 4
View on ClinicalTrials.gov →
Record status
This record was last updated October 20, 2025 (before its estimated March 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this study is to evaluate the antiemetic efficacy and drug safety of ondansetron orodispersible film in pediatric patients with malignant tumors who received moderate emetic risk radiation induced vomiting, and to formulate reasonable and effective clinical medication regimen for preventing vomiting caused by moderate emetic risk radiation in children with malignant tumor.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-10-14.
Trial Details
NCT Number NCT07217600
Lead Sponsor Chongqing University Cancer Hospital
Conditions Radiotherapy-induced Nausea and Vomiting (RINV), Pediatric Cancer
Enrollment 60 participants
Start Date 2025-03-25
Primary Completion 2026-03 (estimated)
Study Completion 2026-04 (estimated)
Updated on ClinicalTrials.gov 2025-10-20